Akèy › Kansè Poumon ki pa ti selil › Arizona › Gilbert
Etid klinik pou Kansè Poumon ki pa ti selil nan Gilbert, AZ
13 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Gilbert (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Banner MD Anderson Cancer Center, Gilbert
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Ap rekriteFaz 3
- Banner MD Anderson Cancer Center ( Site 0181), Gilbert
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Ap rekriteFaz 1
- Research Site, Gilbert
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Banner Health, Gilbert
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Ironwood Cancer & Research Centers, Gilbert
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Ap rekriteFaz 1/2
- Banner MD Anderson Cancer Center, Gilbert
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- Banner Health- MD Anderson Cancer Center, Gilbert
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Banner MD Anderson Cancer Center, Gilbert
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Gilbert
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- Banner MD Anderson Cancer Center, Gilbert
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Ap rekriteFaz 2
- Banner Health MD Anderson, Gilbert
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Banner Health, Gilbert
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Banner MD Anderson Cancer Center, Gilbert
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Gilbert
- Kansè nan tete10 etid
- Kansè kolorektal9 etid
- Kansè (tout kalite)8 etid
- Kansè poumon8 etid
- Kansè vejik6 etid
- Ensifizyans kadyak6 etid
- Myelom Miltip6 etid
- Karsinòm selil skuamèz tèt ak kou6 etid
- Maladi kadyovaskilè6 etid
- Kansè Metastatik6 etid
- Limfom Difize Gwo Selil B5 etid
- Limfòm Non-Hodgkin5 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.